Gefitinib monotherapy in advanced non-small cell lung cancer harboring activating mutation of EGFR had significantly better treatment results comparing to standard chemotherapy - from clinical practice

Abstract

Clinical trials confirmed monotherapy of gefitinib having significantly better treatment results in patients with advanced non-small cell lung cancer harboring activating mutation of EGFR comparing to standard chemotherapy.

Keywords

• Gefitinib
• chemotherapy
• treatments results
• clinical practice